| Biological Information | |
|---|---|
| Background Information: | Complex of N-terminal 6His-tagged recombinant, human p110α full length, containing the mutation H1047R, and untagged recombinant, human p85α full length. The H1047R substitution is a somatic mutation in p110α that has been associated with tumors of the colon, stomach, breast and brain. Combined in vitro and in vitro studies have shown that this mutation confers higher lipid kinase activity than wild type, and is able to induce oncogenic transformation. (Samuels Y. et al., Science, (2004); 304: 554; Kang S. et al., PNAS, (2005);102: 802-807 and Zhao J.J. et al., PNAS, (2005);102:18443-18448). |
| Target Class: | Kinase |
| Family: | Lipid Kinase |
| Accession Number: | U79143 |
| Target Name: | PI3Kα/p85α |
| Target Aliases: | PIK3CA, PI3K, PK3CA |
| Target Species: | Human |
| Usage | |
| Product Type: | Enzymes |
| Application: | Drug Discovery & Development |
| Storage Conditions: | 6 months at -70°C |
| Usage Disclaimer: | These products may be covered by issued US and/or foreign patents, patent application and subject to Limited Use Label License. Please visit discoverx.com/license for a list of products that are governed by limited use label license terms and relevant patent and trademark information. |
PI3-Kinase (p110alpha(H1047R)/p85alpha)
10 µg of PI3 Kinase (p110α (H1047R)/p85α). Complex of N-terminal 6His-tagged recombinant, human p110α full length, containing the mutation H1047R, and untagged recombinant, human p85α full length.
Datasheets
14-792x Datasheet
View Document